3 recruiting, 2 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Extramammary Paget Disease: new trials by email Literature Review of Extramammary Paget Disease trials Research Report on Extramammary Paget Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease Disitamab Vedotin combined with Bicalutamide - Extramammary Paget Disease, Scrotum Disease | Phase 2 | Recruiting | Fudan University | 20 | 2025-08-01 | 2025-08-12 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| Gynecologic Extramammary Paget's Disease Extramammary Paget's Disease, Extramammary Paget Disease | Recruiting | Mayo Clinic | 100 | 2018-02-19 | 2026-01-28 | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
Paget Disease, Extramammary (5) · Carcinoma, Basal Cell (3) · Carcinoma, Merkel Cell (2) · Hemangiosarcoma (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adenocarcinoma, Papillary (1) · Adenocarcinoma, Sebaceous (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basosquamous (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1)
Adenocarcinoma (5) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Ductal, Lobular, and Medullary (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms (4) · Carcinoma, Neuroendocrine (3) · Neoplasms by Site (3) · Neoplasms, Basal Cell (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Nivolumab (2) · Specimen Handling (2) · Biopsy (1) · CTLA-4 Antigen (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · bicalutamide (1) · pembrolizumab (1) · talimogene laherparepvec (1)
National Cancer Institute (NCI) (2) · Fudan University (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1)
United States (4) · China (1) · Guam (1)
Jamie N. Bakkum-Gamez, M.D. (1) · Lara Dunn, MD (1) · Sandip P Patel (1)
PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 37633576, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180888 (1), UM1CA186709 (1), UM1CA186716 (1)